Open AccessDarbepoetin as a neuroprotective agent in mild neonatal encephalopathy: a randomized, placebo-controlled, feasibility trial
Author(s) -
Tara L. DuPont,
Mariana Baserga,
Jean Lowe,
Tara Zamora,
Sandra Sundquist Beauman,
Robin K. Ohls
Publication year - 2021
Publication title -
journal of perinatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.912
H-Index - 94
eISSN - 1476-5543
pISSN - 0743-8346
DOI - 10.1038/s41372-021-01081-y
Subject(s) - medicine , placebo , bayley scales of infant development , randomized controlled trial , intraventricular hemorrhage , population , toddler , anesthesia , pediatrics , gestational age , pregnancy , genetics , cognition , alternative medicine , environmental health , pathology , psychiatry , biology , psychomotor learning , psychology , developmental psychology
To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE).